EIF4A3

Eukaryotic initiation factor 4A-III · P38919 · EIF4A3 on Sugi Atlas →

3,919 patent compounds predicted against EIF4A3, 1,840 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7067642 SCHEMBL7067642 0.53 15/20
SCHEMBL8540533 SCHEMBL8540533 0.53 12/20
SCHEMBL8540536 SCHEMBL8540536 0.53 12/20
SCHEMBL1144973 SCHEMBL1144973 1.00 7/20
SCHEMBL3643479 SCHEMBL3643479 0.77 6/20
SCHEMBL5780183 SCHEMBL5780183 0.69 6/20
SCHEMBL2405536 SCHEMBL2405536 0.50 6/20
SCHEMBL1243969 SCHEMBL1243969 0.49 6/20
SCHEMBL1969597 SCHEMBL1969597 0.46 6/20
SCHEMBL5781992 SCHEMBL5781992 0.68 5/20
SCHEMBL4969673 SCHEMBL4969673 0.47 5/20
SCHEMBL3003964 SCHEMBL3003964 0.43 5/20
SCHEMBL3070760 SCHEMBL3070760 0.39 5/20
SCHEMBL3579630 SCHEMBL3579630 0.39 5/20
SCHEMBL1822934 SCHEMBL1822934 0.68 4/20
SCHEMBL765246 SCHEMBL765246 0.60 4/20
SCHEMBL3639230 SCHEMBL3639230 0.60 4/20
SCHEMBL8919071 SCHEMBL8919071 0.54 4/20
SCHEMBL3366195 SCHEMBL3366195 0.49 4/20
SCHEMBL4397741 SCHEMBL4397741 0.49 4/20

Clinical trials — most relevant to EIF4A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery PHASE2WITHDRAWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors PHASE1ACTIVE_NOT_RECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
MEHMO Natural History and Biomarkers nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
miRNA as a Growth Plate Marker After GH nanUNKNOWN
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma nanWITHDRAWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EIF4A3 binder may also engage these)

ProteinNameSimilarity
A6M931 1.000 A6M931 →
Q4R3Q1 1.000 Q4R3Q1 →
Q2NL22 1.000 Q2NL22 →
Q3B8Q2 1.000 Q3B8Q2 →
Q5ZM36 1.000 Q5ZM36 →
Q91VC3 1.000 Q91VC3 →
B5DG42 1.000 B5DG42 →
B7ZTW1 1.000 B7ZTW1 →
Q7ZVA6 1.000 Q7ZVA6 →
B5FZY7 1.000 B5FZY7 →
O42226 1.000 O42226 →
A7EM88 1.000 A7EM88 →
A6S4N4 1.000 A6S4N4 →
Q5U526 1.000 Q5U526 →
Q5VNM3 1.000 Q5VNM3 →
Q40468 1.000 Q40468 →
Q9VHS8 1.000 Q9VHS8 →
Q5R4X1 1.000 Q5R4X1 →
EIF4A1 Eukaryotic initiation factor 4A-I 1.000 landscape →
Q4WEB4 1.000 Q4WEB4 →
Q4P184 1.000 Q4P184 →
P41380 1.000 P41380 →
P0CQ72 1.000 P0CQ72 →
P0CQ70 1.000 P0CQ70 →
P10630 1.000 P10630 →
EIF4A2 Eukaryotic initiation factor 4A-II 1.000 landscape →
P0CQ73 1.000 P0CQ73 →
Q3SZ65 1.000 Q3SZ65 →
Q10I26 1.000 Q10I26 →
Q41741 1.000 Q41741 →